End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012

167 views

Published on

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
167
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012Published on December 2012 Report SummaryEnd-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012SummaryGlobal Markets Directs, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012, provides anoverview of the indications therapeutic pipeline. This report provides information on the therapeutic development for End-StageKidney Disease (End-Stage Renal Disease or ESRD), complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-StageRenal Disease or ESRD). End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, Half Year is built usingdata and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites and industry-specific third party sources, put together byGlobal Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicateddisease.Scope- A snapshot of the global therapeutic scenario for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies anduniversities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of route of administrationand molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-StageRenal Disease or ESRD).- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitiveadvantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects toenhance and expand business potential and scope.End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 1/7
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Table of ContentTable of ContentsTable of Contents 2List of Tables 5List of Figures 5Introduction 6Global Markets Direct Report Coverage 6End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 7Therapeutics Development 8An Overview of Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 8End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Development by Companies 10End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Investigation by Universities/Institutes 11Late Stage Products 12Comparative Analysis 12Mid Clinical Stage Products 13Comparative Analysis 13Early Clinical Stage Products 14Comparative Analysis 14Pre-Clinical Stage Products 15Comparative Analysis 15End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Products under Development by Companies 16End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Products under Investigation by Universities/Institutes17Companies Involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Development 18Eli Lilly and Company 18Isis Pharmaceuticals, Inc. 19La Jolla Pharmaceutical Company 20Hawthorn Pharmaceuticals, Inc. 21Ardelyx, Inc. 22End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Assessment 23Assessment by Monotherapy Products 23Assessment by Combination Products 24Assessment by Route of Administration 25Assessment by Molecule Type 27Drug Profiles 29tabalumab - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29benazepril hydrochloride - Drug Profile 31Product Description 31Mechanism of Action 31R&D Progress 31End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 2/7
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!valsartan - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33Benazepril + Valsartan - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35Folate + Pyridoxine + Cyanocobalamin - Drug Profile 37Product Description 37Mechanism of Action 37R&D Progress 37Neo-Kidney Augment - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39haw Nuv-15 - Drug Profile 40Product Description 40Mechanism of Action 40R&D Progress 40haw Nuv16 - Drug Profile 41Product Description 41Mechanism of Action 41R&D Progress 41acetylcysteine - Drug Profile 42Product Description 42Mechanism of Action 42R&D Progress 42ISIS-CRPRx - Drug Profile 43Product Description 43Mechanism of Action 43R&D Progress 43LJPC-101 - Drug Profile 44Product Description 44Mechanism of Action 44R&D Progress 44spironolactone - Drug Profile 45Product Description 45Mechanism of Action 45R&D Progress 45RDX-013 - Drug Profile 46Product Description 46Mechanism of Action 46R&D Progress 46End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Drug Profile Updates 47End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Discontinued Products 50End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Dormant Products 51End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Product Development Milestones 52End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 3/7
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Featured News & Press Releases 52Nov 05, 2012: Tengion Receives Notice Of Allowance For US Patent Application Covering Renal Regeneration For Neo-KidneyAugment Product Candidate 52Jul 31, 2012: La Jolla Pharma Announces FDA Agreement With Proposed Phase I Clinical Trial Of GCS-100 In Chronic KidneyDisease 53Jul 31, 2012: Rockwell Medical Completes Patient Enrollment In Phase III Clinical Trials For SFP Iron-Delivery In HemodialysisPatients 53Jun 27, 2012: Rockwell Medical Receives Canadian Patent For SFP-Iron Delivery 53Apr 30, 2012: Rockwell Medical Completes Patient Enrollment In PRIME Clinical Study 54Mar 19, 2012: Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies To Continue as Planned54Dec 12, 2011: Rockwell Medical Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue As Planned 55Nov 14, 2011: KAI Announces Results From Phase II study Of ONO-5163/KAI-4169, Calcium Sensing Receptor Agonist 55Appendix 57Methodology 57Coverage 57Secondary Research 57Primary Research 57Expert Panel Validation 57Contact Us 58Disclaimer 58List of TablesNumber of Products Under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2012 8Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Comparative Analysis, H2 2012 9Number of Products under Development by Companies, H2 2012 10Number of Products under Investigation by Universities/Institutes, H2 2012 11Comparative Analysis by Late Stage Development, H2 2012 12Comparative Analysis by Mid Clinical Stage Development, H2 2012 13Comparative Analysis by Early Clinical Stage Development, H2 2012 14Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15Products under Development by Companies, H2 2012 16Products under Investigation by Universities/Institutes, H2 2012 17Eli Lilly and Company, H2 2012 18Isis Pharmaceuticals, Inc., H2 2012 19La Jolla Pharmaceutical Company, H2 2012 20Hawthorn Pharmaceuticals, Inc., H2 2012 21Ardelyx, Inc., H2 2012 22Assessment by Monotherapy Products, H2 2012 23Assessment by Combination Products, H2 2012 24Assessment by Stage and Route of Administration, H2 2012 26Assessment by Stage and Molecule Type, H2 2012 28End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Drug Profile Updates 47End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Discontinued Products 50End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Dormant Products 51End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 4/7
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!List of FiguresNumber of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2012 8Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Comparative Analysis, H2 2012 9Products under Development by Companies, H2 2012 10Products under Investigation by Universities/Institutes, H2 2012 11Late Stage Products, H2 2012 12Mid Clinical Stage Products, H2 2012 13Early Clinical Stage Products, H2 2012 14Pre-Clinical Stage Products, H2 2012 15Assessment by Monotherapy Products, H2 2012 23Assessment by Combination Products, H2 2012 24Assessment by Route of Administration, H2 2012 25Assessment by Stage and Route of Administration, H2 2012 26Assessment by Molecule Type, H2 2012 27Assessment by Stage and Molecule Type, H2 2012 28End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 5/7
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 6/7
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Pipeline Review, H2 2012 (From Slideshare) Page 7/7

×